Mergers and Acquisitions

GSK to Acquire Sierra Oncology for $1.9 Billion

April 15, 2022

GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9 billion.

Ymmunobio AG Signs Patent Purchase Agreement with LeukoCom GmbH

April 11, 2022

Ymmunobio AG has signed a patent purchase agreement with LeukoCom GmbH to expand its development of cancer therapies.

Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

April 11, 2022

Pfizer plans to acquire ReViral and its respiratory syncytial virus therapeutic candidates to strengthen Pfizer’s capabilities in infectious disease research.

Stanley Capital-Backed Portfolio Company DSS Acquires MyMeds&Me

April 06, 2022

Stanley Capital has announced the acquisition of MyMeds&Me by its portfolio company Drug Safety and Pharmacovigilance Services Solutions.

Emmes Acquires Rare-Disease CRO Casimir

March 18, 2022

Emmes has acquired Casimir, marking its fourth major acquisition.

Biocon Biologics to Acquire Biosimilars Assets from Viatris in $3.3 Billion Deal

March 02, 2022

Biocon Biologics will acquire Viatris’ global biosimilars business, including the company’s portfolio of in-licensed biosimilar assets, in a transaction valued at over $3.3 billion.

Recipharm Acquires Two Biologics CDMOs: Vibalogics and Arranta Bio

February 21, 2022

Recipharm has strengthened its biologics manufacturing capabilities with the acquisition of both Vibalogics and Arranta Bio.

Sartorius Acquires Novasep’s Chromatography Equipment Division

February 10, 2022

Sartorius Stedim Biotech has completed the acquisition of the chromatography equipment division of Novasep.

Pharmasol and PharmaLex Complete Strategic Merger

February 04, 2022

pharmasol has completed the strategic merger with PharmaLex.

Recipharm Acquires Portuguese CDMO, GenIbet, Boosting Biologics Offering

February 01, 2022

Recipharm will build up its biologics service offering with the acquisition of GenIbet.